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Abstract
Although case reports link proton-pump inhibitor (PPI) use and hypomagnesemia, no large-scale 
studies have been conducted. Here we examined the serum magnesium concentration and the 
likelihood of hypomagnesemia (< 1.6 mg/dl) with a history of PPI or histamine-2 receptor 
antagonist used to reduce gastric acid, or use of neither among 11,490 consecutive adult 
admissions to an intensive care unit of a tertiary medical center. Of these, 2632 patients reported 
PPI use prior to admission, while 657 patients were using a histamine-2 receptor antagonist. PPI 
use was associated with 0.012 mg/dl lower adjusted serum magnesium concentration compared to 
users of no acid-suppressive medications, but this effect was restricted to those patients taking 
diuretics. Among the 3286 patients concurrently on diuretics, PPI use was associated with a 
significant increase of hypomagnesemia (odds ratio 1.54) and 0.028 mg/dl lower serum 
magnesium concentration. Among those not using diuretics, PPI use was not associated with 
serum magnesium levels. Histamine-2 receptor antagonist use was not significantly associated 
with magnesium concentration without or with diuretic use. The use of PPI was not associated 
with serum phosphate concentration regardless of diuretic use. Thus, we verify case reports of the 
association between PPI use and hypomagnesemia in those concurrently taking diuretics. Hence, 
serum magnesium concentrations should be followed in susceptible individuals on chronic PPI 
therapy.
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Although proton-pump inhibitors (PPIs) are extremely widely used, with over 100 million 
US prescriptions in 2007,1 increasing attention has focused on the adverse effects of this 
class of medicine, including respiratory infections,2 renal failure,3,4 Clostridium difficile 
colitis,5,6 hip fractures,7 and drug–drug interactions.8 Recently, a potential association 
between chronic PPI use and hypomagnesemia has been reported. Approximately 30 cases 
of severe hypomagnesemia in patients on PPI therapy have been identified in the literature, 
with symptoms ranging from cardiovascular instability to neuroexcitability, including tetany 
and seizures.9–20 In light of these case reports and others from the Adverse Event Reporting 
System, the US Food and Drug Administration released a ‘drug safety communication’ in 
March 2011 regarding the risk of PPI-induced hypomagnesemia. They suggested that health 
care professionals should consider obtaining baseline and periodic follow-up serum 
magnesium levels for those patients expected to be long-term PPI users, particularly among 
those on diuretics and other medicines that could predispose to hypomagnesemia.21
Magnesium, as the second most common intracellular cation, is important in a wide range of 
cellular functions, including protein synthesis, enzymatic reactions, and the regulation of ion 
channels. The classic symptoms of severe hypomagnesemia include tetany, convulsions, 
bradycardia, hypotension, and death.22–24 Even mild hypomagnesemia may be clinically 
important and has been associated with cardiovascular and total mortality,25 possibly 
through effects on left ventricular size,26,27 hypertension,28,29 endothelial function,30 and 
insulin resistance.31
Beyond case reports and a case series,32 little is known about the potential effect of PPI use 
on magnesium concentrations, with no large-scale data currently available. This lack of 
robust data is particularly important given the costs associated with surveillance of 
magnesium levels among patients taking PPIs and the potential risks of hypomagnesemia.
To address these questions, we examined the association of acid-suppressive medication use 
with serum magnesium concentrations in a large sample of patients admitted to a single 
medical center in whom information on current outpatient medication use and admission 
serum magnesium levels was available. Given that the indications for PPI and histamine-2 
receptor antagonist (H2RA) use are similar, we compared both PPIs and H2RA users to 
those not taking acid-suppressive medications.
RESULTS
Patient admission characteristics
Of the 11,490 unique intensive care unit (ICU) admissions from 2001 to 2008, we 
documented PPI use in 23% (n = 2632) before admission, compared with 6% (n = 657) on a 
H2RA. As seen in Table 1, PPI users tended to be older, had worse renal function, and had a 
higher prevalence of comorbidities than those on neither medication.
Relationship of PPI use to magnesium concentrations
As shown in Table 2, baseline unadjusted magnesium concentrations did not differ by type 
of acid-suppressive medication. However, after adjusting for patient demographics and renal 
function (Model I), and in the fully adjusted model (Model II), PPI exposure was 
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significantly associated with lower magnesium concentrations compared with those not 
taking acid-suppressive therapy, in a model adjusted for diuretic use. Age and renal function 
were both important independent confounders that accounted for the change in directionality 
of the effect of PPIs on magnesium concentrations. We did not find a significant association 
between H2RA exposure and magnesium concentration in either model, although the s.e’s 
for this less prevalent exposure were comparatively larger.
Diuretic use significantly modified the effect of PPI exposure on magnesium concentrations 
(P = 0.03 for multiplicative interaction term). As seen in Table 3, diuretic users were similar 
in age, gender, ethnicity, and presence of comorbidities, regardless of PPI or H2RA 
exposure, but had significantly worse renal function. In unadjusted analysis of diuretic users, 
those on a PPI medication had significantly lower magnesium concentrations than those not 
taking acid-suppressive therapies (P = 0.002). In multivariable analysis of those on diuretics 
(Table 2), PPI use was associated with a 0.028 (± 0.007) mg/dl lower serum magnesium 
concentration. In diuretic naive individuals, PPI use was not associated with a change in 
serum magnesium concentration. There was no association between H2RA use and serum 
magnesium concentration in either diuretic or non-diuretic group. An interaction term 
between H2RA use and diuretic use was not significant (P = 0.9).
Relationship of PPI use to hypomagnesemia
We next assessed whether PPI use was related to frank hypomagnesemia, defined as a serum 
magnesium concentration < 1.6 mg/dl. In a fully adjusted analysis, neither PPI nor H2RA 
exposure was associated with hypomagnesemia. However, diuretic use again significantly 
modified the effect of PPI exposure on magnesium concentrations (P < 0.001). As seen in 
Table 4, PPI use was associated with a 54% increased odds of hypomagnesemia in diuretic 
users compared with diuretic users not taking acid-suppressive therapy. PPI use was not 
associated with an increased risk of hypomagnesemia among patients not taking diuretics.
Effect of different types of diuretics on the association between PPI exposure and 
magnesium levels
Given the modifying effect of diuretics, we then assessed whether the type and number of 
diuretic medications further influenced the association between PPI exposure and 
magnesium concentrations. As seen in Table 5, the effects of PPI exposure on magnesium 
concentrations were similar in individuals taking any type of single diuretic agent, although 
the association was strongest in those taking a loop diuretic. The effect of PPI exposure on 
magnesium concentrations was not altered by the use of multiple diuretics. H2RA exposure 
was not associated with differences in magnesium concentrations in any group.
Acid-suppressive medication and phosphate
To test the specificity of our analysis, we also evaluated PPI use and serum phosphate. 
Similar to magnesium, phosphate concentrations are affected by nutritional intake, diuretic 
use, and renal function, yet should not be affected by PPI or H2RA use. Neither PPI nor 
H2RA use was associated with serum phosphate levels, regardless of diuretic use (interaction 
term P-values both > 0.05), in whole cohort analysis or in the subset of diuretics users (all P-
values > 0.05).
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DISCUSSION
In this large hospital-based cross-sectional study, PPI exposure before admission was 
associated with lower serum magnesium concentrations in those patients concurrently using 
diuretics. The combination of diuretic and PPI exposure was associated with an almost 55% 
increased odds of hypomagnesemia compared with those on diuretics who were not taking 
acid-suppressive medications. PPI use was not associated with magnesium in diuretic naive 
individuals.
Although the risk of hypomagnesemia has been suggested by smaller observational studies, 
this study is the first to our knowledge to provide an analysis between PPI use and 
magnesium concentrations in a large sample, and supports the notion that PPI use may lead 
to hypomagnesemia in susceptible individuals.
The mechanism as to how PPI use may lead to hypomagnesemia is not certain. Magnesium 
homeostasis depends on the balance between intestinal absorption and renal excretion. 
Intestinal absorption occurs through two major pathways: active and passive. Active 
transcellular transport across the apical lumen occurs via the channel transient receptor 
potential melastatin 6.33 Passive movement down a concentration gradient occurs 
paracellularly, modulated by the tight junction proteins claudin-16 and claudin-19,34 and is 
postulated to be the major route of magnesium absorption. Renal excretion primarily 
depends on tubular reclamation in the proximal tubule and thick ascending limb via 
paracellular absorption,35 with some active absorption in the distal convoluted tubule.36 
Diuretics, by affecting the electrochemical gradient within the tubular lumen, inhibit tubular 
magnesium reclamation.35,36
Emerging clinical and basic scientific data suggest that PPIs inhibit intestinal absorption 
rather than causing renal wasting. In a case series of hypomagnesemic patients on PPI 
therapy,12 urine magnesium levels were appropriately low. Furthermore, repletion with 
intravenous magnesium rapidly corrected serum concentrations, whereas for many,9,11 but 
not all,13 oral magnesium seemed to have less of an effect. Recent cell culture data suggest 
that PPIs may impair passive magnesium absorption across intestinal epithelial cells.37 
Although H2RA use affects the pH of the gastric epithelium, H2RA use has not been 
associated with hypomagnesemia, suggesting a pH-independent mechanism. Our study 
results also support this distinction.
Although the observed effect size of PPI exposure on magnesium concentration is modest, it 
may reflect larger differences in magnesium homeostasis that are clinically important. 
Because magnesium is primarily stored within the skeleton,38 magnesium efflux from the 
bone may maintain serum concentrations, despite a net negative balance. In a manner similar 
to net acid retention seen in chronic kidney disease, where despite a loss of renal hydrogen 
excretion, serum bicarbonate levels are maintained by efflux of bicarbonate from the bone, 
PPI exposure may lead to a net negative magnesium balance with modest changes in serum 
magnesium concentration. Chronic magnesium egress may induce bone mineral loss, 
potentially explaining the association between long-term PPI use and osteoporosis in several 
observational studies,39,40 although not confirmed by others.41,42 Carefully designed balance 
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studies are needed to further address whether PPI exposure affects net magnesium 
homeostasis independently of serum concentrations.
Given the remarkable popularity of PPIs and the relative paucity of reported cases of 
hypomagnesemia, our findings should be contextualized. It is possible that rare genetic 
variants in magnesium transport channels or cell junction proteins might account for the 
observed cases reports of profound hypomagnesemia, with less generalizability to the larger 
population. However, it is also plausible that chronic PPI use decreases intestinal magnesium 
absorption in all individuals, yet net changes in magnesium balance are prevented by 
compensatory upregulation of renal tubular magnesium reclamation. It is possible that only 
in those with diuretic-induced impairment of renal magnesium reclamation that a negative 
magnesium balance ensues.
There are several important limitations of our analysis. Given the observational nature of the 
study, causality cannot be established between PPI exposure and serum magnesium 
concentration. In addition, as our sample is comprised of critically ill patients, 
generalizability to the outpatient population is uncertain. However, the majority of subjects 
in this analysis were admitted through the Emergency Department, where labs are typically 
drawn upon arrival and reflect pre-hospitalization values. Magnesium levels of patients 
transferred from outside facilities were not likely to represent a true initial serum magnesium 
level and were therefore excluded. In addition, our findings are strengthened by accounting 
for illness-associated predictors of magnesium.
Although MIMIC-II is an exceedingly rich data set and we captured many markers of illness 
severity, unmeasurable preadmission confounders likely exist. We neither had information 
regarding length of illness before presentation, nor information about preceding nutritional 
intake. However, PPI use seemed to have no effect on phosphate, the other major 
nutritionally dependent mineral. In addition, although we included terms for both initial 
serum creatinine and change in creatinine over the first 24 h of hospitalization, our model 
likely does not fully capture the effect of renal function on magnesium given known 
limitations of creatinine-based estimates of kidney function.43 However, because 
unmeasured renal dysfunction should lead to higher magnesium concentrations, and given 
the higher prevalence of renal dysfunction observed among patients taking PPIs, this 
residual confounding would tend to lead to an underestimate of the true association between 
PPI use and hypomagnesemia.
In addition, it is likely that there was misclassification in exposure to acid-suppressive 
medication use and other medications that do not require a prescription. Many forms of 
magnesium supplementation may not have been recorded as a preadmission medication. In 
addition, PPIs became available without a prescription during the study period, likely 
reducing the consistency with which they were reported in admission records. However, if 
misclassification of PPI use is unrelated to serum magnesium levels, then this would likely 
bias our findings toward a false finding of no association.
Finally, as we measured PPI use solely through the identification of the medication on a 
preadmission medication list, we were unable to establish the dose or duration of its use. 
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Given the potential importance of the chronicity of PPI use on serum magnesium, further 
studies that include this information are clearly needed.
In summary, we found that, among a large sample of critically ill patients, magnesium levels 
on admission were lower among patients in whom both PPI and diuretic use was 
documented beforehand. Our findings support the current Food and Drug Administration 
advisory suggesting that PPI use can lead to hypomagnesemia in susceptible individuals. 
Further data from well-designed prospective studies are needed to inform clinical decision-
making regarding monitoring and replacement of magnesium among patients who take these 
widely used medications.
MATERIALS AND METHODS
Study population
We used the MIMIC-II (Multiparameter Intelligent Monitoring in Intensive Care) research 
database, a joint venture managed by researchers from the Laboratory for Computational 
Physiology at Massachusetts Institute of Technology and the Department of Medicine at the 
Beth Israel Deaconess Medical Center (BIDMC).44 BIDMC is a large, urban academic 
medical center. The database contains high temporal resolution data from clinical systems, 
including lab results, electronic documentation, and bedside monitor trends and waveforms, 
for all patients admitted to a BIDMC ICU between 2001 and 2008. Use of the MIMIC II 
database has been approved by the Institutional Review Boards of Beth Israel Deaconess 
Medical Center and the Massachusetts Institute of Technology.
MIMIC-II contains data from 24,581 adult patients who were admitted to surgical or 
medical ICUs at BIDMC. On the basis of ICD-9 codes assigned at discharge, we excluded 
individuals with conditions likely to influence PPI use and magnesium levels, including 
acute and chronic diarrheal illnesses, chronic inflammatory bowel disease, malabsorptive 
conditions, end stage renal disease, preeclampsia, and primary hyperparathyroidism (n = 
2639). Another 5526 patients were excluded because of the lack of an identifiable 
medication section in the initial History and Physical examination upon admission to the 
hospital. Because we could not account for medication exposure or magnesium 
administration while hospitalized at other institutions, 3413 patients transferred from other 
medical facilities were excluded. In addition, we excluded 27 patients with missing 
comorbidity data and 1486 individuals who did not have magnesium levels measured on 
admission, leaving a final sample of 11,490 unique patients. The first hospitalization with an 
ICU stay was used for all patients.
Medication exposure and outcome
PPI or H2RA exposure was defined as any PPI or H2RA listed as a preadmission medication. 
We developed a Natural Language Processing (NLP) algorithm that searched discharge 
summaries for a discrete home medication section within the History and Physical 
examination performed on admission. Of those with an identifiable section, the NLP then 
processed the medications to find individual entries of PPIs, H2RAs, and diuretics. We 
performed a validation of the NLP algorithm by formal physician examination of the 
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discharge summaries of 100 random cases that included patients in five different groups: (1) 
patients with no identifiable home medication section on the discharge summary, (2) those 
taking PPIs, (3) those taking H2RAs, (4) those taking both classes, and (5) patients taking 
neither class. Among these 100 patients, we identified one false-positive case (containing the 
phrase ‘patient has not been taking: cimetidine’) and no false negatives.
Outcome
The primary outcome was the first serum magnesium level recorded within 36 h of 
admission to the hospital. To limit the effect of outliers, all extreme magnesium levels 
(0.5%) were winsorized at the 0.5 and 99.5 percentiles. In addition, to examine potentially 
severe hypomagnesemia, we dichotomized levels at 1.6 mg/dl in concert with our hospital 
laboratory reference and in keeping with previous clinical studies.45,46
As serum phosphate is affected by the balance of nutritional intake and renal excretion in a 
similar fashion to magnesium, we tested phosphate levels as a secondary outcome to ensure 
the specificity of observed associations.
Covariates
Demographic information included age, sex, and ethnicity, coded as White, African 
American, Asian, Hispanic, other, or unknown. Individual predictors of the illness severity, 
averaged over the first 24 h of ICU stay, included systolic blood pressure, heart rate, and 
temperature. On the basis of tests of model fit, we included creatinine as both a linear and 
centered quadratic term, along with a creatinine ratio (repeat creatinine within 24 h of 
admission over admission creatinine) to capture the dynamic nature of renal function in 
critically ill patients. Values of serum glucose, calcium, phosphate, and hematocrit were 
included when obtained within 36 h of admission to the hospital. All 30 comorbidities of the 
Elixhauser score47 were incorporated into the model as separate, independent measures, 
rather than a summary index score. We encoded any type and number of oral diuretics, 
obtained from the admission medication list, as a binary variable. Imputed means were used 
for all variables with missing or implausible values: systolic blood pressure (n = 471), heart 
rate (n = 469), temperature (n = 1749), baseline serum creatinine (n = 13), ratio of 24 h/
baseline creatinine (n = 1043), glucose (n = 23), calcium (n = 1263), phosphate (n = 1261), 
and hematocrit (n = 39).
Statistical analysis
We present baseline characteristics according to use of PPIs, H2RAs, or neither, with group 
differences assessed by analysis of variance. To assess whether acid-suppressive medications 
were related to magnesium concentrations, we developed sequential multivariable linear 
regression models. Binary indicator variables were created for PPI or H2RA use, as well as 
for diuretic use and all Elixhauser comorbidities. Ethnicity was included as a multicategory 
variable. Age, vital signs, and laboratory values were all included as continuous variables. 
Model I included age, gender, ethnicity, and renal function. Model II added admission vital 
signs, laboratory data, comorbidities, and diuretic use, as described above. Model 
diagnostics included visual inspection of residual plots, distribution of the residuals, and 
quantile plots.
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Given the direct effect of diuretic use on magnesium excretion and the nature of the Food 
and Drug Administration alert, we tested for effect modification of the PPI and magnesium 
relationship by diuretic exposure. In these analyses, we used the covariates from Model II, 
along with a multiplicative interaction term, and in the presence of significant interaction, 
we present the results stratified by diuretic use. We also provide the baseline characteristics 
of the diuretics users stratified by use of PPIs, H2RAs, or neither. Differences across all three 
groups were assessed by analysis of variance. Differences between group magnesium 
concentrations were assessed by the Tukey–Kramer test.
To assess the association between acid-suppressive medication use and hypomagnesemia, 
defined as a value less than 1.6 mg/dl, we created comparable logistic regression models. 
The same variables used in the multivariate linear regression were included without further 
dichotomization.
To characterize the effect of diuretic exposure on the association between PPI exposure and 
magnesium concentrations, we also examined models stratified by diuretic class (loop, 
thiazide, other) and those on more than one class of diuretic medications. Sensitivity 
analyses of the complete data set (n = 8948) without imputation revealed similar results in 
both the linear and logistic models. In addition, exclusion of the Elixhauser comorbidity 
‘Fluid and Electrolyte Disorders’ did not lead to meaningful differences in the results. 
Analysis of only those individuals admitted through the Emergency Department (n = 9108) 
revealed similar results. In addition, as the effect of PPI exposure was observed in diuretic 
users, we performed analyses of this subset using complete data (n = 2358) and using those 
admitted through the Emergency Department (n = 2619), without significant differences in 
the reported results. Finally, to test the specificity of our analysis, serum phosphate 
concentrations were used as a continuous dependent variable in multivariable analysis of the 
whole cohort and of the subset of diuretic users. All analyses were performed using JMP Pro 
(SAS Institute, Cary, NC).
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Table 1
Baseline characteristics by acid suppression medication
Proton-pump inhibitors
(n = 2632)
H2 receptor antagonists
(n = 657)
No acid-suppressive
medications (n = 8201) P-valuea
Age, mean (s.d.), years 67.8 (15.4) 66.9 (15.9) 61.1 (19.2) < 0.001
Male, no. (%) 1403 (53.3) 368 (56.3) 4796 (58.5) < 0.001
Ethnicity, no. (%)
  White 2022 (76.8) 496 (75.5) 6054 (73.8) < 0.001
  African American 245 (9.3) 61 (9.3) 682 (8.3) < 0.001
  Hispanic or Latino 79 (3.0) 19 (2.9) 292 (3.6) < 0.001
  Asian 59 (2.2) 14 (2.1) 225 (2.7) < 0.001
  Other 52 (2.0) 10 (1.52) 244 (3.0) < 0.001
  Unknown 175 (6.7) 57 (8.7) 704 (8.6) < 0.001
Past medical history, no. (%)
  Hypertension 1009 (38.4) 253 (38.5) 2749 (33.5) < 0.001
  Diabetes 749 (28.5) 184 (28.0) 1671 (20.4) < 0.001
  Congestive heart failure 623 (23.7) 143 (21.8) 1215 (14.8) < 0.001
  Liver disease 210 (8.0) 36 (5.5) 331 (4.0) < 0.001
  Renal failure 164 (6.2) 41 (6.2) 255 (3.1) < 0.001
  Metastatic cancer 158 (6.0) 41 (6.2) 382 (4.7) 0.010
  Alcohol abuse 120 (4.6) 22 (3.4) 555 (6.8) < 0.001
  Psychoses 95 (3.6) 30 (4.6) 330 (4.0) 0.46
Vital signs, mean (s.d.)
  Temperature, °C 36.8 (0.59) 36.8 (0.57) 36.9 (0.60) < 0.001
  Systolic blood pressure, mm Hg 119.8 (17.5) 120.5 (16.6) 120.1 (16.8) 0.60
  Heart rate, /min 75.4 (13.6) 76.0 (13.1) 76.1 (13.5) 0.067
Laboratory values on admission, mean (s.d.)
  Magnesium, mg/dl 1.93 (0.41) 1.93 (0.38) 1.91 (0.40) 0.24
  Calcium, mg/dl 8.61 (0.83) 8.65 (0.88) 8.57 (0.87) 0.004
  Phosphate, mg/dl 3.68 (1.28) 3.66 (1.14) 3.58 (1.17) < 0.001
  Creatinine, mg/dl 1.50 (1.52) 1.34 (1.22) 1.22 (1.20) < 0.001
  Ratio of 24 h/baseline serum creatinine 0.99 (0.31) 1.06 (0.60) 1.01 (0.34) < 0.001
  Glucose, mg/dl 153.1 (90.5) 154.6 (92.8) 152.2 (98.3) 0.77
  Hematocrit, % 33.6 (6.4) 34.5 (6.3) 35.5 (6.7) < 0.001
Diuretic use, no. (%) 1034 (39.3) 229 (34.9) 2023 (24.7) < 0.001
Abbreviation: H2, histamine-2.
aP-values reflect across-group differences.
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Table 3
Baseline characteristics of diuretic users
Proton-pump
inhibitors (n = 1034)
H2 receptor
antagonists (n = 229)
No acid-suppressive
medications (n = 2023) P-valuea
Age, mean (s.d.), years 70.6 (13.8) 71.3 (13.2) 71.4 (13.8) 0.29
Male, no. (%) 513 (49.6) 115 (50.2) 1084 (53.6) 0.10
Ethnicity, no. (%)
  White 776 (75.1) 173 (75.6) 1506 (74.4) 0.35
  African American 117 (11.3) 26 (11.4) 219 (10.8) 0.35
  Hispanic or Latino 36 (3.5) 6 (2.6) 46 (2.3) 0.35
  Asian 18 (1.7) 2 (0.87) 34 (1.7) 0.35
  Other 23 (2.2) 4 (1.8) 41 (2.0) 0.35
  Unknown 64 (6.2) 18 (7.9) 177 (8.8) 0.35
Past medical history, no. (%)
  Hypertension 425 (41.1) 98 (42.8) 868 (42.9) 0.63
  Diabetes 344 (33.3) 77 (33.6) 648 (32.0) 0.74
  Congestive heart failure 391 (37.8) 81 (35.4) 636 (31.4) 0.002
  Liver disease 123 (11.9) 16 (7.0) 91 (4.5) < 0.001
  Renal failure 55 (5.3) 14 (6.1) 102 (5.0) 0.78
  Metastatic cancer 39 (3.8) 11 (4.8) 82 (4.1) 0.77
  Alcohol abuse 49 (4.7) 9 (3.9) 66 (3.3) 0.14
  Psychoses 33 (3.2) 2 (0.9) 54 (2.7) 0.09
Vital signs, mean (s.d.)
  Temperature, °C 36.8 (0.60) 36.7 (0.56) 36.8 (0.58) 0.50
  Systolic blood pressure, mm Hg 120.0 (18.2) 120.4 (16.8) 119.3 (17.0) 0.43
  Heart rate, /min 73.9 (13.3) 73.9 (13.7) 73.5 (12.8) 0.70
Laboratory values on admission, mean (s.d.)
  Magnesium, mg/dl 1.96 (0.42) 2.0 (0.39) 2.0 (0.41) 0.002
  Calcium, mg/dl 8.66 (0.82) 8.74 (0.85) 8.72 (0.80) 0.15
  Phosphate, mg/dl 3.76 (1.32) 3.78 (1.14) 3.74 (1.23) 0.82
  Creatinine, mg/dl 1.57 (1.28) 1.45 (1.08) 1.44 (1.10) 0.008
  Ratio of 24 h/baseline serum creatinine 0.97 (0.23) 1.02 (0.28) 1.01 (0.31) < 0.001
  Glucose, mg/dl 156.4 (92.0) 153.8 (97.9) 162.1 (113.2) 0.25
  Hematocrit, % 33.4 (6.33) 33.5 (6.10) 34.5 (6.70) < 0.001
Abbreviation: H2, histamine-2
aP-values reflect across-group differences.
Kidney Int. Author manuscript; available in PMC 2017 November 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Danziger et al. Page 14
Ta
bl
e 
4
A
ss
oc
ia
tio
n 
be
tw
ee
n 
ac
id
 su
pp
re
ss
io
n 
th
er
ap
y 
an
d 
hy
po
m
ag
ne
se
m
ia
a
Pr
o
to
n-
pu
m
p 
in
hi
bi
to
rs
H
2 
re
ce
pt
or
 a
nt
ag
on
ist
s
N
o 
ac
id
-s
up
pr
es
siv
e 
m
ed
ic
at
io
ns
C
as
es
,
n
 
(%
)
O
dd
s r
at
io
(95
%
 C
I)
P-
v
a
lu
e
C
as
es
,
n
 
(%
)
O
dd
s r
at
io
(95
%
 C
I)
P-
v
a
lu
e
C
as
es
,
n
 
(%
)
R
ef
.
St
ud
y 
po
pu
la
tio
nb
40
5 
(15
.3)
1.
10
 (0
.96
–1
.25
)
0.
18
94
 (1
4.3
)
0.
97
 (0
.76
–1
.23
)
0.
81
13
62
 (1
6.6
)
—
D
iu
re
tic
 u
se
 (n
 
=
 3
28
6)
16
1 
(15
.6)
1.
54
 (1
.22
–1
.95
)
<
 0
.0
01
17
 (7
.4)
0.
63
 (0
.36
–1
.03
)
0.
07
22
3 
(11
.0)
—
N
o 
di
ur
et
ic
 u
se
 (n
 
=
 8
20
4)
24
4 
(15
.2)
0.
92
 (0
.78
–1
.09
)
0.
35
77
 (1
8.0
)
1.
14
 (0
.85
–1
.49
)
0.
39
11
39
 (1
8.4
)
—
A
bb
re
v
ia
tio
ns
: H
2,
 
hi
sta
m
in
e-
2;
 R
ef
., 
re
fe
re
nc
e 
ca
te
go
ry
.
R
ef
er
en
ce
 c
at
eg
or
y 
is 
th
os
e 
on
 n
o 
ac
id
-s
up
pr
es
siv
e 
m
ed
ic
at
io
ns
.
a A
dju
ste
d a
na
lys
is 
usi
ng
 al
l v
ar
ia
bl
es
 fr
om
 M
od
el
 II
, w
ith
 m
ag
ne
siu
m
 d
ic
ho
to
m
iz
ed
 a
t <
 1
.6
 m
g/
dl
.
b A
 m
ul
tip
lic
at
iv
e 
in
te
ra
ct
io
n 
te
rm
 b
et
w
ee
n 
pr
ot
on
-p
um
p 
in
hi
bi
to
r (
PP
I) 
an
d d
iur
eti
c u
se 
wa
s 
sig
ni
fic
an
t (
P 
<
 0
.0
01
). A
 m
ult
ipl
ica
tiv
e 
in
te
ra
ct
io
n 
te
rm
 b
et
w
ee
n 
hi
sta
m
in
e-
2 
re
ce
pt
or
 a
nt
ag
on
ist
 (H
2R
A
) a
nd
 
di
ur
et
ic
 u
se
 w
as
 a
lso
 si
gn
ifi
ca
nt
 (P
 
=
 0
.0
1).
Kidney Int. Author manuscript; available in PMC 2017 November 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Danziger et al. Page 15
Ta
bl
e 
5
Ef
fe
ct
 o
f d
iu
re
tic
 ty
pe
 o
n 
as
so
ci
at
io
n 
be
tw
ee
n 
ac
id
 su
pp
re
ss
io
n 
th
er
ap
y 
an
d 
se
ru
m
 m
ag
ne
siu
m
 c
on
ce
nt
ra
tio
ns
Se
ru
m
 m
ag
ne
siu
m
 co
nc
en
tr
at
io
n 
(m
g/d
l)
Pr
o
to
n-
pu
m
p 
in
hi
bi
to
rs
H
2 
re
ce
pt
or
N
o 
ac
id
-s
up
pr
es
siv
e 
m
ed
ic
at
io
ns
R
ef
.
β-C
oe
ffi
ci
en
t ±
 s.
e.
P-
v
a
lu
e
β-C
oe
ffi
ci
en
t ±
 s.
e.
P-
v
a
lu
e
Th
ia
zi
de
 d
iu
re
tic
s (
n
 
=
 9
94
)
−
0.
02
7 
± 
0.
01
5
0.
07
−
0.
01
3 
± 
0.
02
8
0.
63
—
Lo
op
 d
iu
re
tic
s (
n
 
=
 1
63
1)
−
0.
03
0 
± 
0.
01
0
0.
00
3
−
0.
00
4 
± 
0.
01
8
0.
80
—
O
th
er
 d
iu
re
tic
s (
n
 
=
 8
9)
−
0.
02
6 
± 
0.
05
5
0.
63
−
0.
08
4 
± 
0.
13
3
0.
54
—
M
ul
tip
le
 (n
 
=
 5
72
)
−
0.
03
3 
± 
0.
01
8
0.
06
−
0.
03
3 
± 
0.
03
0
0.
27
—
A
bb
re
v
ia
tio
ns
: H
2,
 
hi
sta
m
in
e-
2;
 R
ef
., 
re
fe
re
nc
e 
ca
te
go
ry
.
R
ef
er
en
ce
 c
at
eg
or
y 
is 
th
os
e 
on
 n
o 
ac
id
-s
up
pr
es
siv
e 
m
ed
ic
at
io
ns
 w
ith
in
 e
ac
h 
di
ur
et
ic
 c
la
ss
. β
-
Co
ef
fic
ie
nt
s ±
 s.
e’
s a
nd
 P
-
v
al
ue
s a
re
 p
ro
v
id
ed
 fo
r e
ac
h 
va
ria
bl
e.
Kidney Int. Author manuscript; available in PMC 2017 November 12.
